Immuneering Corp

For the period ended Jun 30, 2026. Filed Aug 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 5, 2026

IMRX$3.65-0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.

	IMMUNEERING CORPORATION
Date: August 5, 2026	By:	/s/ Benjamin J. Zeskind
	Name:	Benjamin J. Zeskind, Ph.D.
	Title:	Co-Founder, President, Chief Executive Officer and Director (Principal Executive Officer)
Date: August 5, 2026	By:	/s/ Andrew Gengos
	Name:	Andrew Gengos
	Title:	Chief Financial Officer and Treasurer(Principal Financial Officer)
Date: August 5, 2026	By:	/s/ Mallory Morales
	Name:	Mallory Morales
	Title:	SVP Finance, Chief Accounting Officer and Assistant Treasurer(Principal Accounting Officer)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.